PM mOOvers ๐Ÿ‘€ $AGTC - Applied Genetic Technologies Reports 6-Month Data From Ongoing Phase 1/2 Trial In X-Linked Retinitis Rigmentosa $VBIV - VBI Vaccines Reports Second Pivotal Phase 3 Study Of Sci-B Met Primary, Secondary Endpoints $ELTK - Eltek Ltd. Receives an Additional Order for up to $1.4 Million From a Governmental Authority $TLSA -Tiziana Life Sciences Highlights Phase 1 Data Showing Oral Treatment With Foralumab Well Tolerated
  • 1